Video

Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC

Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.

Ruth Aiwu He, MD, PhD, scientific lead in liver and biliary cancers at Georgetown-Lombardi Comprehensive Cancer Center, discusses the results of the LEGACY study in patients with hepatocellular carcinoma (HCC).

The LEGACY study was a retrospective analysis of patients with early-stage HCC who received Y-90 glass microspheres (TheraSphere), according to He. In the overall cohort, Y-90 demonstrated a best overall response rate of 88%, with a complete response rate of 83%, says He.

Additionally, the therapy resulted in prolonged disease control, and the 3-year overall survival rate in patients with transplant or resection following Y-90 was 93%, says He. Overall, the results of the study appear to be quite promising, He concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity